[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Karyopharm Therapeutics Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,85,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100235452","phase-1-selinexor-and-backbone-treatments-of-multiple-myeloma-patients-100235452",false,"NCT02343042","Selinexor and Backbone Treatments of Multiple Myeloma Patients","A Phase 1b\u002F2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed\u002FRefractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma","STOMP","Inclusion Criteria:\n\n1. Written informed consent signed in accordance with federal, local, and institutional guidelines.\n2. Age greater than or equal to (≥) 18 years at the time of informed consent.\n3. Histologically confirmed diagnosis with measurable disease for relapsed\u002Frefractory myeloma.\n4. Symptomatic MM, based on IMWG guidelines.\n5. Patients must have measurable disease as defined by at least one of the following:\n\n   1. Serum M-protein ≥ 0.5 gram per deciliter (g\u002FdL) by serum protein electrophoresis (SPEP) or, for immunoglobulin A (IgA) myeloma, by quantitative IgA\n   2. Urinary M-protein excretion at least 200 mg\u002F24 hours\n   3. Serum free light chain (FLC) ≥ 100 milligram per liter (mg\u002FL), provided that FLC ratio is abnormal\n   4. If SPEP is felt to be unreliable for routine M-protein measurement (example, for IgA MM), then quantitative immunoglobulin (Ig) levels by nephelometry or turbidometry are acceptable\n6. Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #22) that patients had from treatments in previous clinical studies must have resolved to less than or equal (≤) Grade 2 by C1D1.\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.\n8. Adequate hepatic function within 28 days prior to C1D1:\n\n   * For SPd, SRd, and SPEd: Total bilirubin \\\u003C 2\\* upper limit of normal (ULN) (except patients with Gilbert's syndrome \\[hereditary indirect hyperbilirubinemia\\] who must have a total bilirubin of ≤ 3\\* ULN) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2.5\\* ULN\n   * For SVd, SPVd, SDd, SNd, SBd and SDPd: Total bilirubin of \\\u003C 1.5\\* ULN (except patients with Gilbert's syndrome \\[hereditary indirect hyperbilirubinemia\\] who must have a total bilirubin of ≤ 3\\* ULN) and both AST and ALT \\\u003C 2.0\\* ULN\n   * For SKd and SMd: Total bilirubin \\\u003C 2x ULN (except patients with Gilbert's syndrome \\[hereditary indirect hyperbilirubinemia\\] who must have a total bilirubin of ≤ 3x ULN) and both AST and ALT \\\u003C 3.0x ULN\n9. Adequate renal function within 28 days prior to C1D1. For Arms 1-11, estimated creatinine clearance (CrCl) calculated using the formula of Cockroft and Gault (1976).\n\n   * ≥ 20 milliliter per minute (mL\u002Fmin) for SVd, SDd, and SKd arms\n   * ≥ 30 mL\u002Fmin for SNd, SBd, and SMd arms\n   * ≥ 45 mL\u002Fmin for SPd, SPVd, SPEd and SDPd arms\n   * \\> 60 mL\u002Fmin for SRd arm\n10. Adequate hematopoietic function within 28 days prior to C1D1: absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3, hemoglobin (Hb) ≥ 8.0 g\u002FdL, and platelet count ≥ 100,000\u002Fmm\\^3.\n\n    * SPVd (Arm 4) and SKd (Arm 6) only: platelet count ≥150,000.\n    * SMd (Arm 12) only: platelet count ≥75,000 for subjects in whom \\\u003C50% of bone marrow nucleated cells are plasma cells; or platelet count \\\u003C50,000 for subjects in whom ≥50% of bone marrow nucleated cells are plasma cells.\n11. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients must use highly effective methods of contraception throughout the study and for 90 days following the last dose of study treatment. For Arm 12 (SMd), all study subjects must agree and adhere to all testing and contraception requirements as specified in the mezigdomide Global Pregnancy Prevention Plan (PPP)\n\n    SPd (Arm 1) Only.\n12. Relapsed or refractory MM with:\n\n    1. Documented evidence of progressive disease (PD) after achieving at least stable disease (SD) for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)\n    2. ≤ 25 percent (%) response (i.e., patients never achieved ≥ MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM)\n    3. Previously undergone ≥ 2 cycles of lenalidomide and a PI (in separate therapeutic regimens \\[not for maintenance\\] or in combination)\n    4. In the expansion arm at RP2D, patients must not be pomalidomide refractory\n\n    SVd (Arm 2) Only:\n13. Relapsed or refractory MM with:\n\n    1. Documented evidence of relapse after ≥ 1 previous line of therapy\n    2. Not refractory to bortezomib in their most recent line of therapy\n\n    SRd in RRMM (Arm 3) Only:\n14. Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as long as patient's MM was not refractory to prior lenalidomide; patients whose MM was refractory to lenalidomide maintenance regimens will be allowed in this cohort).\n\n    SPVd (Arm 4) Only:\n15. Patients who received 1- 3 prior lines of therapy, including ≥ 2 cycles of lenalidomide and have demonstrated disease progression on their last therapy (may include prior bortezomib, as long as the patient's MM was not refractory to bortezomib therapy), but patients must be pomalidomide-naïve in the Dose Expansion at RP2D (Cohort 4.3 ONLY).\n\n    SDd (Arm 5) Only:\n16. Patients who received ≥ 3 prior lines of therapy, including a PI and an immunomodulatory agent (IMiD), or patients with MM refractory to both a PI and an IMiD.\n17. Patients must not have received prior anti-cluster of differentiation 38 (anti-CD38) monoclonal antibodies (Cohort 5.3 ONLY - Dose Expansion at RP2D).\n\n    SKd (Arm 6) Only:\n18. Patients may have received prior PIs; however, their MM must NOT be refractory to carfilzomib.\n\n    SRd in NDMM (Arm 7) Only:\n19. Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria (calcium elevation, renal failure, anemia, lytic bone lesions) or myeloma-defining events and need systemic therapy. No prior systemic therapy for NDMM is permitted other than pulse dose dexamethasone (maximum dose of 160 mg) or corticosteroid equivalent.\n\n    SNd (Arm 8) Only:\n20. Patients must have MM that relapsed after 1 - 3 prior lines of therapy (may not include those with MM refractory to bortezomib or carfilzomib but patients must be ixazomib-naïve).\n\n    SPEd (Arm 9) Only:\n21. Patients who received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor (in separate or the same regimens), but patients must be pomalidomide-naive and elotuzumab-naive in the Dose Expansion at RP2D (Cohort 9.3 ONLY).\n\n    SBd (Arm 10) Only:\n22. Patients who have MM that was refractory to an IMiD, a proteasome inhibitor, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody. Patients must be belantamab mafodotin-naive in the Dose Expansion cohort at RP2D (Cohort 10.3 ONLY).\n\n    SDPd (Arm 11) Only:\n23. Patients who received 1-3 prior therapies, including lenalidomide and a proteasome inhibitor (in separate or the same regimen), but patients must be pomalidomide-naive and daratumumab-naive in the Dose Expansion cohort at RP2D (Cohort 11.3 ONLY).\n\n    SMd (Arm 12) only:\n24. Patients with RRMM who have received at least 2 prior lines of therapy, including an IMiD, a PI, and an anti-CD38 monoclonal antibody. Patients must have either failed a T-cell redirecting treatment (eg, CAR-T or bispecific antibody) or otherwise cannot receive such therapy due to either medical or logistic reasons.\n\nExclusion Criteria:\n\nPatients meeting any of the following exclusion criteria are not eligible to enroll in this study:\n\n1. Smoldering MM.\n2. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and quantitative immunoglobulin levels cannot be used instead.\n3. Documented active systemic amyloid light chain amyloidosis.\n4. Active plasma cell leukemia.\n5. Red Blood Cell (RBC) and platelet transfusions and blood growth factors within 14 days of C1D1 (Arms 1-11 only). Red blood cells and platelet transfusions and blood growth factors within 7 days of C1D1 (Arm 12).\n6. Platelet transfusion or G-CSF within 7 days or pegfilgastrim within 14 days prior to the complete blood count (CBC) used to determine eligibility.\n7. Radiation, chemotherapy, or immunotherapy or any other tumor-directed therapy ≤ 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Spot radiation is permitted at any time for treatment of fractures or to prevent fractures as well as for pain management.\n8. Patients with history of spinal cord compression with residual paraplegia (Dose Escalation Phase only).\n9. Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1.\n10. Prior autologous stem cell transplantation \\\u003C 1 month, or allogeneic stem cell transplantation \\\u003C 3 months prior to C1D1.\n11. Active graft versus host disease after allogeneic stem cell transplantation.\n12. Life expectancy \\\u003C 3 months.\n13. Major surgery within 4 weeks prior to C1D1.\n14. Active, unstable cardiovascular function:\n\n    1. Symptomatic ischemia, or\n    2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block\u002Fright bundle branch block (LAFB\u002FRBBB) will not be excluded), or\n    3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or\n    4. Myocardial infarction (MI) within 3 months prior to C1D1\n    5. Ejection fraction (EF) \\\u003C 50% at Screening (Arms 1-11 only, screening echocardiogram not required for Arm 12, SMd)\n15. Uncontrolled active hypertension (Arms 1-11 only).\n16. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose.\n17. Known active hepatitis A, B or C.\n18. Known human immunodeficiency virus (HIV) infection or HIV seropositivity.\n19. Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.\n20. Currently pregnant or breastfeeding.\n21. A serious active psychiatric or active medical condition which, in the opinion of the Investigator, could interfere with treatment.\n22. Hypersensitivity to any of the treatments for the arm in which the patient is enrolled.\n23. SVd Arm (Arm 2), SPVd (Arm 4), and SNd Arm (Arm 8) only: Prior history of neuropathy Grade \\> 2, or Grade ≥ 2 neuropathy with pain at Screening (within 28 days prior to C1D1).\n24. Patients who are eligible for the selinexor PK Run-in only: Treatment with moderate or strong inhibitors\u002Finducers of CYP3A within 7 days prior to Day 1 of the PK Run-in period.\n25. Patients who are eligible for the selinexor PK Run-in only: Not able to receive a strong CYP3A4 inhibitor due to concomitant medications.\n26. SKd arm only: HBs Ag + plus HBc Ab + even though no active hepatitis B virus (HBV) hepatitis. If HBs Ag - plus HBc Ab +, treating physician needs to contact the medical monitor.\n27. Prior exposure to a selective inhibitor of nuclear export (SINE) compound, including selinexor.\n\n    SBd (Arm 10): Only:\n28. Current corneal epithelial disease except mild punctate keratopathy.\n\n    SMd (Arm 12 only):\n29. History of allogeneic stem cell or solid organ transplant at any time.\n30. History of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide (including ≥Grade 3 rash during prior thalidomide, lenalidomide, or pomalidomide therapy), carfilzomib or dexamethasone, any CELMoD agents, or the excipients contained in the formulations, or subject has any contraindications per local prescribing information.\n31. Subject is unable or unwilling to agree to refrain from donating blood while on study intervention, during dose interruptions, and for at least 28 days following the last dose of study intervention.\n32. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.\n33. Use of strong CYP3A4 modulator or proton-pump inhibitors (eg, omeprazole, lansoprazole), within 2 weeks of starting study intervention.\n34. Active concomitant malignancies or history of another malignancy within 3 years prior to C1D1 except for adequately treated early-stage basal cell or squamous cell carcinoma of skin, adequately treated carcinoma in situ of breast or cervix, or organ confined prostate cancer.\n35. History of chronic hepatitis B with detectable viral load.\n36. Subject is unable or unwilling to receive protocol-required dual antiemetic prophylaxis","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation\u002F-evaluation and expansion phases, for the treatment of patients with relapsed\u002Frefractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are:\n\n* Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete\n* Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete\n* Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete\n* Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete\n* Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete\n* Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete\n* Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete\n* Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete\n* Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete\n* Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete\n* Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete\n* Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting\n\nSelinexor pharmacokinetics:\n\n* PK Run-in (Days 1-14):\n\nStarting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 \\[SPVd\\], Arm 6 \\[SKd\\], Arm 8 \\[SNd\\], Arm 9 \\[SPEd\\], Arm 10 \\[SBd\\], and Arm 11 \\[SDPd\\]) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor. This run-in period does not apply to Arm 12 (SMd).",[28],"Multiple Myeloma",[30,31,15,28,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Selinexor","KCP-330","Relapsed\u002FRefractory","Dexamethasone","Pomalidomide","Bortezomib","Karyopharm","Lenalidomide","Daratumumab","Newly Diagnosed","Carfilzomib","Ixazomib","Elotuzumab","Clarithromycin","Belantamab mafodotin","Mezigdomide","CC-92480","BMS-986348","RECRUITING","2026-07-14",{"date":51,"type":52},"2026-07-15","ACTUAL",{"date":54,"type":52},"2015-10",{"date":56,"type":21},"2027-04",{"name":58,"class":59},"Karyopharm Therapeutics Inc","INDUSTRY",25,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":78,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":84,"locationsCount":4},"100609534","karyopharm-expanded-access-program-for-selinexor-100609534","NCT07215832","Karyopharm Expanded Access Program for Selinexor","KEAP","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.",[28,71,72,73,74,75,76,77],"Diffuse Large B-Cell Lymphoma (DLBCL)","Sarcoma","Neuroglioblastoma","Peripheral T-cell Lymphoma","Endometrial Cancer","Myelofibrosis","Other",[79],"selinexor","AVAILABLE","2026-02-26",{"date":83,"type":52},"2026-03-02",{"name":58,"class":59},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100514615","phase-2-a-study-of-selinexor-monotherapy-in-subjects-with-jak-inhibitor-nave-myelofibrosis-and-moderate-thrombocytopenia-100514615","NCT05980806","A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","SENTRY-2","Key Inclusion Criteria:\n\n* A diagnosis of MF or post-ET or post-PV MF according to the 2016 World Health Organization (WHO) classification of MPN, confirmed by the most recent local pathology report\n* Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than or equal to (\\>=) 450 cubic square centimeter (cm\\^3) by MRI or CT scan (results from MRI or CT imaging performed within 28 days prior to C1D1 are acceptable)\n* DIPSS risk category of intermediate-1 with symptoms, or intermediate-2, or high-risk\n* ECOG Performance Status less than or equal to (\\\u003C=) 2\n* Platelet count of greater than or equal to (\\>=) 50 x 10\\^9\u002FL without platelet transfusion within 7 days prior to the first dose of selinexor\n* Absolute neutrophil count (ANC) \\>=1.0 × 10\\^9\u002FL without need for growth factors within 7 days prior to the first dose of selinexor\n* Adequate liver function as defined by the following: aspartate transaminase (AST) and alanine transaminase (ALT) \\\u003C= 2.5 × upper limit normal (ULN) and serum total bilirubin \\\u003C= 3×ULN\n* Calculated creatinine clearance (CrCl) greater than (\\>) 15 milliliter per minute (mL\u002Fmin) based on the Cockcroft and Gault formula\n* Active symptoms of MF as determined by presence of at least 2 symptoms with an average score \\>= 5 or total score of \\>= 12 at screening (at least 5 of 7 consecutive days immediately preceding C1D1) using the MFSAF V4.0\n* Must provide bone marrow biopsy samples (samples obtained up to 3 months prior to C1D1 are permitted) at screening and during the study\n* Currently not eligible for stem cell transplantation\n* Must be willing to complete the MFSAF V4.0 daily during the study for evaluating the symptom response (i.e., TSS50)\n\nKey Exclusion Criteria:\n\n* More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase)\n* Previous treatment with JAK inhibitors for MF\n* Previous treatment with selinexor or other XPO1 inhibitors\n* Females who are pregnant or lactating\n* Prior splenectomy, splenic radiation, or a splenic embolization within 6 months prior to C1D1\n* History of myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), cerebrovascular accident (transient ischemic attack \\[TIA\\]), ventricular arrhythmias, congestive heart failure class \\> 2 per New York Heart Association (NYHA) within 6 months of C1D1\n* Unable to tolerate two forms of antiemetics prior to each dose for the first two cycles",{"count":94,"type":21},58,[25],"The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.",[76,98,99],"Moderate Thrombocytopenia","Mild Thrombocytopenia",[76,30,101,102,103,104,105,106,107,108,109,110,111,112],"Total Symptom Score","Myelofibrosis Symptom Assessment Form","Spleen Volume Reduction","TSS50","SVR35","JAK2","KPT-330","Pacritinib","Ruxolitinib","Momelotinib","Thrombocytopenia","Abs-TSS","2026-02-10",{"date":115,"type":52},"2026-02-12",{"date":117,"type":52},"2024-04-22",{"date":119,"type":21},"2028-10",{"name":58,"class":59},70,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100394316","phase-2-a-study-of-selinexor-seli--low-dose-dexamethasone-ldd-in-penta-refractory-multiple-myeloma-mm-seli-and-bortezomib--ldd-in-triple-class-refractory-mm-100394316","NCT04414475","A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Age greater than or equal to (\\>=)18 years at the time of signing informed consent.\n* Written informed consent in accordance with federal, local, and institutional guidelines.\n* Measurable MM based on IMWG guidelines as defined by at least one of the following:\n\n  1. Serum M-protein \\>= 0.5 gram per deciliter (g\u002FdL) by serum protein electrophoresis (SPEP) or, for Immunoglobulin (Ig) A myeloma, by quantitative IgA.\n  2. Urinary M-protein excretion \\>= 200 mg\u002F24 hours.\n  3. Free light chain (FLC) \\>= 100 milligram per liter (mg\u002FL), provided that the FLC ratio is abnormal.\n* Only for arms Sd-40 BIW, Sd-100 QW and Sd-80 BIW prior to protocol version (PV) 5.0: Participants must have relapsed or refractory multiple myeloma (RRMM) and have previously received at least 4 anti-MM prior therapies and have MM that is refractory to previous treatment with at least 2 proteasome inhibitors (PIs), at least 2 immunomodulatory agent (IMiDs), and 1 anti-cluster of differentiation (CD38) monoclonal antibody. Refractory is defined as lesser than or equal to (\\\u003C=) 25 percent (%) response to therapy, or progression during therapy or progression within 60 days after completion of therapy.\n* Only for Arms Sd-40 BIW and Sd-100 QW as of PV 5.0: Participants must have RR MM and have been previously treated with \\>=3 anti-MM therapies (with exposure to at least 2 PI drugs, at least 2 IMiDs, and 1 anti-CD38 monoclonal antibody), and be refractory to at least 1 drug of each class (PI\u002FIMiD\u002Fanti-CD38). Refractory is defined as \\\u003C=25% response to therapy or progression during therapy or progression within 60 days after completion of therapy.\n* Only for arm SVd: Participants must have previously received 1 to 5 anti-MM prior therapies and have MM that is refractory to previous treatment with at least 1 PI, at least 1 IMiD, and 1 anti- CD38 monoclonal antibody.\n* Eastern Cooperative Oncology Group (ECOG) performance status of \\\u003C= 2.\n* Female participants of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female participants, effective methods of contraception must be used throughout the study and for 7 months for female and 4 months for male following the discontinuation of study treatment.\n\nExclusion Criteria:\n\n* Active plasma cell leukemia.\n* Documented systemic amyloid light chain amyloidosis.\n* Active central nervous system MM.\n* Only for SVd arm: Greater than Grade 2 peripheral neuropathy or Grade \\>= 2 peripheral neuropathy with pain at baseline, regardless of whether or not the participant is currently receiving medication.\n* Radiation, chemotherapy, immunotherapy, or any other anticancer therapy (including investigational therapies) \\\u003C= 2 weeks prior to Cycle 1 Day 1 (C1D1). (Steroids are permitted up to 1 pulse of 40 mg per day for 4 days in the 2 weeks prior to C1D1).\n* Active graft vs. host disease (after allogeneic stem cell transplantation) at C1D1.\n* Ongoing clinically significant non-hematological toxicities from prior treatments that are Grade greater than (\\>) 2 at C1D1.\n* Inadequate hepatic function defined as total bilirubin \\>= 2x upper limit of normal (ULN) (\\>= 3x ULN for participants with Gilbert's syndrome), aspartate transaminase (AST) \\>= 2.5x ULN, and alanine transaminase (ALT) \\>= 2.5x ULN.\n* Inadequate renal function defined as estimated creatinine clearance of lesser than (\\\u003C) 20 milliliter per minute (mL\u002Fmin), calculated using the formula of Cockroft and Gault.\n* Inadequate hematopoietic function defined as the following:\n\n  1. Absolute neutrophil count (ANC) \\\u003C 1000\u002Fcubic millimeter (mm\\^3)\n  2. Platelet count \\\u003C 75,000\u002Fmm\\^3\n  3. Hemoglobin (Hb) level \\\u003C 8.5 g\u002FdL\n* Life expectancy of \\\u003C 4 months, based on the opinion of the Investigator.\n* Major surgery within 4 weeks prior to C1D1.\n* Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose.\n* Active gastrointestinal dysfunction interfering with the ability to swallow tablets, or any gastrointestinal dysfunction that could interfere with absorption of the study treatment.\n* Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus RNA or hepatitis B virus surface antigen.\n* Female participants who are pregnant or lactating.\n* Known intolerance, hypersensitivity, or contraindication to glucocorticoid therapy at C1D1.\n* Concurrent therapy with approved or investigational anticancer therapeutic including topical therapies.\n* Prior exposure to a SINE compound, including selinexor.\n* Serious, active psychiatric or active medical conditions which, in the opinion of the Investigator or the Sponsor, could interfere with the participation in the study.\n* Contraindication to any of the required concomitant drugs or supportive treatments.",{"count":130,"type":21},127,[25],"The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.",[134],"Multiple Myeloma, Refractory",[28,30,136,137,107],"Penta-refractory Multiple Myeloma","Triple-class Refractory Multiple Myeloma","2026-01-30",{"date":140,"type":52},"2026-02-02",{"date":142,"type":52},"2020-07-01",{"date":144,"type":21},"2028-01",{"name":58,"class":59},16,""]